It was a pleasure to discuss with Prof. Atul Deodhar (Oregon Health & Science University, Portland, OR, USA) the results from the further exploratory analysis of the phase 2 trial (NCT03881059) investigating the TYK2 inhibitor, deucravacitinib, in patients with psoriatic arthritis treated with and without background conventional synthetic DMARDs.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract entitled ‘Deucravacitinib Efficacy in Psoriatic Arthritis (PsA) by Baseline DMARD Use: Exploratory Analysis from a Phase 2 Study’ (ABSTRACT NUMBER: 1352) was presented at the ACR Convergence, 5-9 November 2021.
Questions
- Could you tell us a little about deucravacitinib, its mechanism of action and its potential advantages over other kinase inhibitors? (0:14)
- What did the phase 2 study teach us about deucravacitinib in patients with active PsA? (1:36)
- Could you tell us about the current exploratory analysis of the phase 2 study data, and its findings? (3:25)
Disclosures: Prof. Atul Deodhar has been a consultant/ advisory board member for AbbVie, Amgen, Aurinia, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Glaxo Smith & Kline, Janssen, Moonlake, Novartis, Pfizer and UCB, and received research grants from AbbVie, Eli Lilly, Glaxo Smith & Kline, Novartis, Pfizer and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
